14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

“…The advent of new anti-tuberculosis drugs such as delamanid and bedaquiline should allow the development of more effective, better tolerated and shorter treatment regimens for DR-TB, which would also improve treatment adherence. [35][36][37][38] In addition, reinforced communication, with closer and regular contact between health services and the patient, including substance abuse treatment, during the out-patient phase should help reduce default rates.…”

Novel Treatments for Drug-Resistant Tuberculosis

“…We have already discussed the role of novel treatment regimens in the context of pretomanid, which has been studied most rigorously in the setting of the novel combination treatment PaMZ. [33][34][35] The importance of new combinations of medications has been highlighted by early experience with the Bangladesh regimen, which has shown particular promise in terms of maintaining high therapeutic efficacy in the setting of a reduced treatment course for MDR-TB. 56 Many novel treatment regimens are currently being investigated, and key aspects of ongoing trials are summarized in Table 3.…”

Pulmonary Tuberculosis Management: 2015 Update

“…They have shown potentialities to improve treatment outcomes for MDR-TB 5,43-51 . They are currently in phase II/III clinical trials (Table 4) 45,46,48,50,51 . Based on the available evidence, the WHO 47 recommends the use of delamanid at a dose of 100 mg twice daily for six months, added to OBR in adults, when pharmacovigilance is in place and informed consent ensured.…”

“…Interestingly, the addition of Z increased the activity of both bedaquiline and pretomanid 39,[48][49][50] .…”